Episode Details
Back to EpisodesEp. 119: Phase 2 HOPE clinical trial results
Published 1 year, 4 months ago
Description
Moderator: Theodoros M. Mavridis (Dublin, Ireland)
Guest: Messoud Ashina (Glostrup, Denmark)
In this episode Theodoros M. Mavridis and Messoud Ashina delve into the findings of the Phase 2 HOPE clinical trial, which assesses the efficacy and safety of Lu
Moderator: Theodoros M. Mavridis (Dublin, Ireland)
Guest: Messoud Ashina (Glostrup, Denmark)
In this episode Theodoros M. Mavridis and Messoud Ashina delve into the findings of the Phase 2 HOPE clinical trial, which assesses the efficacy and safety of Lu AG09222, a monoclonal antibody that targets the PACAP pathway. They explore the potential of this innovative treatment for migraine prevention while highlighting the critical role of the PACAP pathway in migraine pathophysiology.